(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 16.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.59%.
Alnylam Pharmaceuticals's revenue in 2026 is $5,013,242,000.On average, 35 Wall Street analysts forecast ALNY's revenue for 2026 to be $742,014,171,040, with the lowest ALNY revenue forecast at $686,564,014,576, and the highest ALNY revenue forecast at $782,865,131,720. On average, 34 Wall Street analysts forecast ALNY's revenue for 2027 to be $903,810,762,848, with the lowest ALNY revenue forecast at $726,343,474,648, and the highest ALNY revenue forecast at $1,118,646,634,752.
In 2028, ALNY is forecast to generate $1,070,027,294,664 in revenue, with the lowest revenue forecast at $813,268,961,472 and the highest revenue forecast at $1,368,306,276,416.